Core Insights - VERAXA Biotech AG is preparing for a NASDAQ listing and is showcasing its Bi-targeted Tumor-Associated Cytotoxicity (BiTAC) platform at major industry conferences [1][2][7] - The company is focused on developing dual-target oncology therapies with reduced off-tumor toxicity and is currently pursuing nine discovery and development programs [2][6] - Voyager Acquisition Corp. is acting as the special purpose acquisition company (SPAC) for VERAXA's business combination, with Cantor Fitzgerald providing capital markets advisory services [3][8] Conference Participation - VERAXA will attend the ASCO Annual Meeting from May 30 to June 3, 2025, in Chicago, IL, where key executives will be available for meetings [4] - The BIO International Convention will take place from June 16 to 19, 2025, in Boston, MA, with opportunities for stakeholders to connect with VERAXA's leadership [5] Business Combination Details - A definitive business combination agreement was signed on April 22, 2025, between VERAXA and Voyager Acquisition Corp., which will lead to VERAXA becoming publicly traded on NASDAQ [7] - The transaction is supported by Anne Martina Group as the M&A advisor [7] Company Overview - VERAXA is focused on next-generation antibody-based therapeutics, including bispecific antibody-drug conjugates (ADCs) and T-cell engagers (TCEs), leveraging transformative technologies [6] - The company was founded on scientific breakthroughs from the European Molecular Biology Laboratory, emphasizing its commitment to innovative life science research [6]

Core Insights - Datadog AI Research has launched two significant projects: Toto, an open-weights foundation model for observability, and BOOM, the largest public benchmark for observability metrics [1][2][4] Group 1: Datadog AI Research Initiatives - Toto is the first open-source foundation model focused on observability, trained on Datadog's internal telemetry metrics, achieving superior performance compared to existing time series foundation models (TSFMs) [2][3] - BOOM provides a comprehensive benchmark with 350 million observations across 2,807 real-world multivariate series, addressing unique challenges in production telemetry [4][5] Group 2: Technical Features and Benefits - Toto's zero-shot forecasting capability allows for immediate anomaly detection and capacity planning without the need for per-series tuning, which is essential for monitoring billions of ephemeral time series [3][5] - BOOM serves as an actively maintained resource for the research community, facilitating advancements in forecasting models specific to observability metrics [4][6] Group 3: Future Directions and Collaboration - Datadog AI Research aims to continuously release AI projects and collaborate with applied AI teams to develop tools that address customer challenges and enhance engineering workflows [5][6] - The open-source nature of Toto and BOOM invites contributions from the research and open-source software communities to advance observability forecasting [6]